HLN Haleon plc

9.050USD-0.33%Mkt Cap: 39.67B USDP/E: 18.47

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the As…

Institutional holders20 on file

Key Statistics

Company
Market Cap39.67B USD
Enterprise Value47.82B USD
Revenue (TTM)14.69B USD
Gross Profit9.32B USD
Net Income (TTM)2.20B USD
Revenue/Share3.30 USD
Last Price9.050 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees24.5K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)18.47
P/E (Forward)14.97
PEG2.10
EV/EBITDA16.79
EV/Revenue3.26
P/S3.56
P/B1.83
EPS (TTM)0.65 USD
EPS (Forward)0.80 USD
52W Range
8.38023% of range11.28
52W High11.28 USD
52W Low8.380 USD
Profitability
Gross Margin64.19%
Oper. Margin23.48%
EBITDA Margin25.54%
Profit Margin15.11%
ROE10.15%
ROA5.11%
ROIC7.91%
ROCE8.71%
Growth
Revenue Growth2.20%
Earnings Growth-4.50%
Cash Flow & Leverage
Operating CF3.47B USD
CapEx (TTM)543.86M USD
FCF Margin16.16%
FCF Yield5.98%
Net Debt9.78B USD
Net Debt/EBITDA2.61
Net Debt/FCF4.12
Balance Sheet
Debt/Equity0.52
Current Ratio0.69
Quick Ratio0.51
Book Value/Sh6.50 USD
Cash/Share0.24 USD
Dividends
Fwd Div Rate0.20 USD
Trail. Div Rate0.07 USD
Div. Yield2.18%
5Y Avg Yield—
Payout Ratio40.08%
Ex-Div DateAug 14, 2026
Pay DateSep 17, 2026
Analyst Consensus
Rating—
Target (Mean)10.40 USD
Upside (mean)+14.9%
Target Range9.790 USD – 11.40 USD
9.790+14.9% to mean11.40
# Analysts5
Ownership
Shares Out.4.38B
Float4.43B
Insiders0.03%
Institutions15.71%
Short Interest
Short Ratio0.8d
Short % Float0.33%
Short % Out.0.33%
Shares Short14.59M
Short (prev mo.)24.84M
Technical
SMA 509.330 (-3.0%)
SMA 2009.701 (-6.7%)
Beta0.29
S&P 52W Chg12.08%
Avg Vol (30d)20.61M
Avg Vol (10d)22.06M
Technical Indicators
RSI (14)43.8
MACD-0.1167
MACD Signal-0.1120
MACD Hist.-0.0048
BB Upper10.23 USD
BB Middle9.233 USD
BB Lower8.238 USD
BB Width21.57%
ATR (14)0.2109 USD
Vol Ratio (20d)0.58x

About Haleon (NYSE: HLN)

›

Haleon (NYSE: HLN) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 24,535 employees.

The shares were at 9.050 USD on 19 November 2026, down 4.0% over 52 weeks. Its 52-week range is 8.380 USD to 11.28 USD: the price is 19.8% below the high and 8.0% above the low.

At a market capitalisation of 39.67B USD, it trades at 18.5 times trailing earnings and 15.0 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 26.3, a discount of 30% for HLN. It pays a dividend yielding 2.18% (it pays out 40% of its earnings), against a median of 1.85% among the dividend payers in that peer group.

Haleon reports return on equity of 10.1%, an operating margin of 23.5% and revenue up 2.2% year over year.

Its debt exceeds its cash by 7.43B GBP, a debt-to-equity ratio of 0.52. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 5 analysts cover the stock; their mean price target of 10.40 USD is 14.9% above the current price. The next earnings report is expected on 24 February 2027.